Skip to main content

Edible Garden Posts 9% Revenue Growth as Non-Perishable CPG Units Surge 49.3% Year-Over-Year

Hydroponic Basil, Potted Herbs, and Wheatgrass Accelerate; International Nutraceutical Sales Nearly Double Year-Over-Year Company’s Portfolio Optimization and Expansion into CEA-Informed, Better-For-You Shelf Stable Categories Pushes Market Penetration and Growth Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced financial results for the third quarter ended September 30, 2025. The third quarter is traditionally the slowest of the year for Edible Garden, however the results reflect the early benefits of the Company’s strategic evolution toward a CEA informed...

Continue reading

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down...

Continue reading

PCS Edventures! Announces Results for the Second Quarter of Fiscal Year 2026

MERIDIAN, Idaho, Nov. 14, 2025 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its second quarter of fiscal year 2026, which ended on September 30, 2025. Second Quarter FY 2026 Overview:Revenue decreased 32.5% to $1,529,503 in the second quarter of FY 2026 compared to the prior year. Gross margin of 58.0% in the second quarter of FY 2026 compared to 59.7% in the second quarter of FY 2025. Net income before income tax provision was $0.00 million in the second quarter of FY 2026 versus $0.55 million in the previous year same quarter. During the quarter, shares outstanding declined 3.3% as 3,967,283 shares were repurchased.Mike Bledsoe, President, commented, “This quarter marked...

Continue reading

Atlas Energy Reports Third Quarter 2025 Financial Results

CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its unaudited consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended September 30, 2025, are available on the Company’s SEDAR+ profile at www.sedarplus.ca. “The recent moderation in global oil prices and emerging forecasts for a potential oversupply in 2026 have added to an already constructive environment for disciplined capital deployment. These market dynamics have contributed to a meaningful expansion of Atlas’s deal pipeline over the last few months and strengthened the visibility of near-term actionable opportunities”, said Mark Hodgson, Atlas Energy’s President and Chief Executive Officer. “Within...

Continue reading

Picard Reports Third Quarter 2025 Financial Results

– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., commented, “The third quarter marked a pivotal moment for the company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring convertible debt, providing new capital to accelerate research, development, and commercial expansion across SynCardia’s life-saving artificial...

Continue reading

NexLiving Communities Reports Record Q3 2025 Results and Declares Quarterly Dividend

HALIFAX, Nova Scotia, Nov. 14, 2025 (GLOBE NEWSWIRE) — NexLiving Communities Inc. (“NexLiving” or the “Company”) announced operating and financial results for the three-month and nine-month periods ended September 30, 2025. Stavro Stathonikos, President & CEO commented: “2025 has so far been a year of strong execution producing a milestone quarter for NexLiving. Q3 FFO per share was the highest ever, having increased +30% year-over-year, driven by both operational improvements and acquisition growth. In late Q2 we brought management of our Saint John portfolio in-house, resulting in a +13% increase in same-property NOI. Our recent Winnipeg acquisition is already contributing to FFO, and as construction progresses on our five-phase Ottawa townhome project, we expect to exercise our cashless option and add high-quality assets...

Continue reading

Iterum Therapeutics Reports Third Quarter 2025 Financial Results

–-Commercially Launched ORLYNVAH™ in the United States in August 2025– –Extended Cash Runway into Q2 2026– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. “We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “The significance of this milestone cannot...

Continue reading

Next Hydrogen Reports Q3 2025 Financial Results

MISSISSAUGA, Ontario, Nov. 14, 2025 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the third quarter ended September 30, 2025. “Last week, we announced a transformative financing following the successful commissioning of our electrolyzer at the largest onsite hydrogen fueling station in Ontario. We view this as a testament to our proprietary electrolyzer technology for cost-effective clean hydrogen production,” said Raveel Afzaal, President & CEO of Next Hydrogen. “This financing, once closed, is expected to fully fund us to cashflow positive while enabling us to scale our existing product line and launch our larger product line. We will execute on a capital light strategy...

Continue reading

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma  MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) cGMP manufacturing collaboration established with Cellipont Bioservices HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based therapies, today reported corporate updates and financial results for the third quarter ended September 30, 2025. “Marker entered the second half of 2025 with strong...

Continue reading

AtlasClear Holdings Reports Fiscal First Quarter 2026 Results and Provides Corporate Update Including Elimination of Prior Going Concern Uncertainty

Earnings Call Scheduled for Friday, November 14, 2025, at 8:30 AM ET $20 Million in New Financing Completed Subsequent to Quarter-End De-SPAC Liabilities Reduced by Over 80% Since Fiscal 2024 Stockholders’ Equity Positive at $6.9 Million Third Correspondent Clearing Customer Signed and OnboardingTAMPA, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear Holdings” or the “Company”) today announced its financial results for the fiscal first quarter ended September 30, 2025, and provided a corporate update. The Company will host its earnings conference call this morning at 8:30 AM Eastern Time. “This quarter marks a key inflection point for AtlasClear,” said John Schaible, Executive Chairman of AtlasClear Holdings. “We have achieved positive stockholders’ equity, continued to streamline...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.